London, Jan 29, 2026, 09:03 GMT — Regular session
Haleon shares were down 0.5% at 370.6 pence by 0849 GMT, extending a two-day decline and lagging a firmer wider market, data showed. Britain’s FTSE 100 was up about 0.6% at the same time. Haleon opened at 371.7 pence and traded between 370.5 and 372.2 pence, with about 229,000 shares changing hands early in the session.
There was no fresh company news to pin the move on, leaving the Sensodyne maker drifting with broader risk appetite. On Wednesday, the FTSE 100 closed down 0.5% as investors turned cautious ahead of the U.S. Federal Reserve decision, and “there seems to have been a rotation out of European and U.K. stocks in favour of U.S. technology stocks,” said Axel Rudolph, senior financial analyst at IG. Reuters
London’s morning agenda has been dominated by earnings, with banks back in focus. Lloyds Banking Group reported a better-than-expected 12% rise in annual profit and lifted its 2026 profitability target; CEO Charlie Nunn said the bank’s momentum allowed it to “upgrade guidance.” Reuters
Haleon sells consumer healthcare products across oral health, vitamins and supplements, and pain relief, among other categories. Its brands include Sensodyne, Polident and Parodontax, as well as Panadol and Advil, according to its company profile.
For Haleon investors, the immediate question is whether the stock can shake off the recent softness without a fresh catalyst. Attention is already shifting to the next set of company numbers and any signal on demand trends and margins.
The backdrop is still being set by global earnings headlines, especially in tech. Microsoft shares fell about 6% in Frankfurt after it reported record AI spending and slower cloud-computing growth, a reminder of how quickly sentiment can flip.
But Haleon can still do its own damage if guidance disappoints. A softer outlook for 2026 or weaker organic growth — sales growth that strips out currency and acquisitions — would likely weigh, and a sharp swing in exchange rates can muddy the picture for companies with global revenue.
The next clear catalyst is Haleon’s full-year 2025 results on Feb. 25, followed by a first-quarter trading update on April 29, the company’s events calendar shows.
Related articles: LSE:HLN
